The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 21, No. 2, pp. 177-180.
© 1987 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sylvester, R.
Right arrow Articles by Lobell, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sylvester, R.
Right arrow Articles by Lobell, M


Research Articles

Cytarabine-induced cerebellar syndrome: case report and literature review

RK Sylvester, AJ Fisher, and M Lobell

High-dose cytarabine (HDARAC) therapy is an effective regimen in treating refractory leukemias. A typical regimen is cytarabine 3 g/m2 iv over one to three hours q 12h for a total of 8 to 12 doses. This case report illustrates the neurotoxicity unique to HDARAC. The patient received two cycles of HDARAC over the course of a ten-week period. During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC. These symptoms resolved over a period of five days. Six weeks later a more severe syndrome of dysarthria and ataxia developed during a second cycle of treatment. These symptoms worsened over 24 hours despite discontinuation of therapy, then gradually decreased in severity but persisted until his death two months later. The neurotoxicity seen with HDARAC is dose-related and has occurred in up to 60 percent of treated patients. The incidence of cerebellar toxicity approaches 30 percent, with irreversible ataxia reported in up to 16.7 percent. Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of HDARAC is recommended.


This article has been cited by other articles:


Home page
J. Neurosci.Home page
M. Colon-Cesario, J. Wang, X. Ramos, H. G. Garcia, J. J. Davila, J. Laguna, C. Rosado, and S. Pena de Ortiz
An inhibitor of DNA recombination blocks memory consolidation, but not reconsolidation, in context fear conditioning.
J. Neurosci., May 17, 2006; 26(20): 5524 - 5533.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. G. Besirli and E. M. Johnson Jr.
JNK-independent Activation of c-Jun during Neuronal Apoptosis Induced by Multiple DNA-damaging Agents
J. Biol. Chem., June 13, 2003; 278(25): 22357 - 22366.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Vera, P. Rohrlich, J. L. Stievenart, M. Elmaleh, M. Duval, F. Bonnin, B. Bok, and E. Vilmer
Contribution of Single-Photon Emission Computed Tomography in the Diagnosis and Follow-Up of CNS Toxicity of a Cytarabine-Containing Regimen in Pediatric Leukemia
J. Clin. Oncol., September 1, 1999; 17(9): 2804 - 2804.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. Tomkins, S. Edwards, and A. Tolkovsky
Apoptosis is induced in post-mitotic rat sympathetic neurons by arabinosides and topoisomerase II inhibitors in the presence of NGF
J. Cell Sci., January 6, 1994; 107(6): 1499 - 1507.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1987 by Harvey Whitney Books Company.